Mediclinic International (LON:MDC) was upgraded by JPMorgan Chase & Co., stock analysts, to an “overweight” rating on Monday, Jan. 7, 2019, according to a report that was released. Presently, the brokerage has GBX 394 ($5.15) target price on the stock. This is down from the previous target price GBX 480 ($6.27). JPMorgan Chase & Co.’s target price points to a potential upside of 24.80 percent from the current price of the stock.
MDC has been the topic of numerous reports. Barclays lowered shares of Mediclinic International to an “equal weight” rating. Additionally, they lowered their price target for the stock from GBX 660 ($8.62) to GBX 460 ($6.01) in a research report released on Oct. 18, 2018. On Oct. 2, Citigroup upgraded shares of Mediclinic International to a “buy” rating. Finally, in a report released on Oct. 25, HSBC upgraded shares of Mediclinic International to a “hold” rating. Additionally, HSBC decreased their target price for the company from GBX 540 ($7.06) to GBX 390 ($5.10).
Four investment analysts have given the stock a hold rating and two have given it a buy rating. Mediclinic International has a consensus of a hold rating and an average target price of GBX 488.80 ($6.39).
On Monday, Jan. 14, 2019, shares of LON MDC opened at GBX 315.70 ($4.13). The company has a 52-week low of GBX 495.40 ($6.47) and a 52-week high of GBX 890.18 ($11.63).
Mediclinic International, along with its subsidiaries, operates private hospitals. They offer acute care, specialist-oriented, and multidisciplinary healthcare services. The company operates 17 private acute care hospitals and four clinics with 1,805 inpatient beds in Switzerland; 49 acute care private hospitals and two day clinics in South Africa, three hospitals in Namibia with 8,131 inpatient beds; six acute care private hospitals and 22 clinics with 748 inpatient beds in the United Arab Emirates.
JPMorgan Chase & Co. cut the price target of Cobham (LON:COB) from GBX 130 ($1.70) to GBX 115 ($1.50). This was revealed in a research report published on Thursday, Jan. 12. Currently, the company has a neutral stock rating.
Other analysts have also commented on COB. UBS Group reissued a buy rating on shares of Cobham in a research note on Nov. 15, 2018. Barclays cut the target price on Cobham from GBX 135 ($1.76) to GBX 110 ($1.44) and set an equal weight rating on the stock in a research report on Nov. 19, 2018. On Nov. 29, Berenberg Bank raised Cobham to a buy rating and cut the target price of the stock from GBX 140 ($1.83) to GBX 124 ($1.62). In a research report released on Dec. 4, Deutsche Bank raised Cobham to a hold rating and raised the stock target price from GBX 115 ($1.50) to GBX 120 ($1.57). Finally, Goldman Sachs Group reaffirmed a sell rating on shares of Cobham. Three research analysts rated the stock with a sell rating, five assigned it a hold rating, and three gave it a buy rating. The stock has a consensus rating of hold and an average target price of GBC 123.90 ($1.62).
During midday trading on Thursday, Jan, 12, 2019, shares traded up GBX 0.95 ($0.01) reaching GBX 104.80 ($1.37). The stock had a trading volume of 2,985,686 shares compared to its average volume of 9,760,000. Cobham has a a 52-week low of GBX 107.67 ($1.41) and a 52-week high of GBX 150.30 ($1.96).
Cobham pic provides a range of technologies and services to commercial, defense, aerospace, space, and security markets in the United Kingdom, the United States, other European countries, Australia, Asia, and internationally. There are four segments the company operates: communications and connectivity, mission systems, advanced electronic solutions, and aviation services.
Smith & Nephew (LON:SN)’s stock had its neutral rating reiterated by analysts at JPMorgan Chase & Co. on Jan. 8, 2019. Currently, the company has a GBX 1,477 ($19.30) price objective on the stock. JPMorgan Chase & Co.’s target price indicates a potential upside of 3.94 percent from the previous close.
Other equities research analysts commented on SN recently. Deutsche Bank reaffirmed a sell rating on shares of SN on Oct. 5, 2018. On Oct. 16, HSBC downgraded SN to a hold rating and increased the target price from GBX 1,400 ($18.29) to GBX 1,500 ($19.60). Berenberg Bank increased the target price of Smith & Nephew from GBX 1,370 ($17.90) to GBX 1,475 ($19.27) and rated the stock on hold on Nov. 2, 2018. Finally, Morgan Stanley raised Smith & Nephew on Dec. 10 to an overweight rating and increased the target price for the stock from GBX 1,475 ($19.04) to GBX 1,692 ($22.11).
Seven investment analysts have rated the stock with a hold rating and two have given the company a buy rating. Presently, the stock has an average hold rating and a consensus price target of GBX 1,457.67 ($19.05.)
On Tuesday, Jan. 10, shares of LON:SN opened at GBX 1,421 ($18.57). Smith & Nephew has a 52-week low of GBX 1,173 ($15.33) and a 52-week high of GBC 1,442 ($18.84).
Smith & Nephew plc designs develops, designs, and sells medical devices around the world. The company offers sports medicine joint repair products for surgeons. This includes an array of instruments, technologies, and implants necessary to perform minimally invasive surgery on the joints.
By Jeanette Smith
Modern Readers: Mediclinic International (LON:MDC) Upgraded to “Overweight” at JPMorgan Chase & Co.
Bharatapress: COBHAM (COB) TARGET PRICE CUT TO GBX 115 BY ANALYSTS AT JPMORGAN CHASE & CO.
Modern Readers: JPMorgan Chase & Co. Reiterates Neutral Rating for Smith & Nephew (LON:SN)
Image Courtesy of geralt’s Pixabay Page – Creative Commons License